论文部分内容阅读
目的比较阿德福韦酯与拉米夫定治疗活动性肝炎肝硬化的临床疗效。方法选取2013年6月—2014年5月遵义市第一人民医院收治的60例活动性肝炎肝硬化患者,分成对照组和观察组,各30例。对照组患者采用阿德福韦酯治疗,观察组患者采用拉米夫定治疗。比较两组患者治疗前后的肝功能及治疗后不同时间点的HBVDAN转阴率。结果治疗前两组患者肝功能比较,差异无统计学意义(P>0.05),治疗后两组患者肝功能比较,差异有统计学意义(P<0.05)。治疗12、24周时两组患者的HBV-DAN转阴率比较,差异无统计学意义(P>0.05),治疗36、48周时观察组患者的HBV-DAN转阴率高于对照组,差异有统计学意义(P<0.05)。结论与阿德福韦酯比较,拉米夫定治疗活动性肝炎肝硬化患者的临床疗效更为显著。
Objective To compare the clinical efficacy of adefovir dipivoxil and lamivudine in the treatment of active cirrhosis. Methods Sixty patients with active cirrhosis who were admitted to the First People’s Hospital of Zunyi from June 2013 to May 2014 were selected and divided into control group and observation group, with 30 cases in each group. The control group was treated with adefovir dipivoxil and the observation group was treated with lamivudine. The liver function before and after treatment and the negative conversion rate of HBVDAN at different time points after treatment were compared between the two groups. Results There was no significant difference in liver function between the two groups before treatment (P> 0.05). There was significant difference in liver function between the two groups after treatment (P <0.05). HBV-DNA negative rates in two groups at 12 and 24 weeks after treatment were not significantly different (P> 0.05). At 36 and 48 weeks, HBV-DNA negative rates in observation group were higher than those in control group, The difference was statistically significant (P <0.05). Conclusions Compared with adefovir dipivoxil, the clinical efficacy of lamivudine in patients with active cirrhosis is more significant.